Medtronic and Corsano Are Building the Hospital-to-Home Wearable Stack
BiohackingMedtronic isn’t building its next wearable — it’s integrating one. The partnership with Corsano Health moves clinical-grade continuous monitoring into a distribution model that could redefine how recovery is tracked outside the hospital.
What Happened
Medtronic announced an exclusive distribution agreement to bring Corsano Health’s multi-parameter wearable into its US HealthCast patient monitoring platform. Corsano is a Dutch medtech company whose device carries FDA clearance and has been deployed in European emergency departments, surgical units, and cardiac care settings since 2025.
The Corsano wearable continuously tracks heart rate, blood oxygen levels, skin temperature, activity levels, and respiratory rate — five parameters that, when monitored together, provide the clinical signal density that spot-checks and single-parameter monitors can’t match. The integration into HealthCast enables a hospital-to-home monitoring arc: from pre-operative baseline through surgical recovery and into post-discharge follow-up.
Kate Benedict, president of Medtronic’s Acute Care & Monitoring business, described the partnership as expanding “our US portfolio of wearable patient monitoring solutions, helping to protect more patients in more settings.”
Why It Matters
The clinical wearable problem isn’t data collection — hospitals generate more monitoring data than clinical teams can meaningfully review. The documented challenge is alarm fatigue: excessive alerts that overwhelm clinicians rather than direct attention. Medtronic’s stated goal for the Corsano integration is transforming raw multi-parameter data into actionable clinical insights — which is a filtering and signal-interpretation problem as much as a hardware one.
The hospital-to-home arc matters because the highest-risk period for many post-surgical patients is the 30 days after discharge, when clinical oversight drops sharply. A device that a patient wears at home and connects to the same monitoring infrastructure as the hospital stay creates a continuity of signal that current discharge models don’t provide. For healthcare systems measuring readmission rates, that continuity has direct economic implications.
The choice to partner rather than develop in-house reflects a pattern in medical device strategy: regulatory-cleared hardware with proven clinical performance is faster to integrate than to build, and Corsano’s European track record de-risks the US rollout.
The So What
For the biohacking and health-optimization community, the Medtronic-Corsano partnership signals where the wearable market is heading. Devices like the Clair continuous hormone monitor and Osteoboost’s FDA-cleared bone wearable represent the consumer edge of a clinical-grade wearable trend that Medtronic is now formalizing at the hospital level. As multi-parameter monitoring moves from ICU to discharge to home, the infrastructure being built now determines which consumer devices eventually connect to clinical data rails. Corsano’s integration into HealthCast is one step in that direction.
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →